Starpharma sees impressive new data published

Company News

by Rachael Jones

Pharmaceutical Starpharma (ASX:SPL) today announced impressive data from AstraZeneca published by the World Intellectual Property Organisation.

The patent for Starpharma’s DEP delivery technology with AstraZeneca’s inhibitor is highly effective across a range of cancer types including leukemias.

Starpharma CEO, Dr Jackie Fairley says the combination with blockbuster products shows a strong synergy, also with other leading anti-cancer drugs and that this could represent an important additional benefit for the DEP platform.

Shares in Starpharma (ASX:SPL) are trading 12.17 per cent higher to $1.29.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.